VCYT vs. PSNL, GTH, BNR, RDNT, GH, FTRE, CDNA, VRDN, FLGT, and CELC
Should you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Personalis (PSNL), Genetron (GTH), Burning Rock Biotech (BNR), RadNet (RDNT), Guardant Health (GH), Fortrea (FTRE), CareDx (CDNA), Viridian Therapeutics (VRDN), Fulgent Genetics (FLGT), and Celcuity (CELC).
Personalis (NASDAQ:PSNL) and Veracyte (NASDAQ:VCYT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.
Personalis has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.
61.9% of Personalis shares are held by institutional investors. 4.1% of Personalis shares are held by company insiders. Comparatively, 1.3% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Veracyte had 2 more articles in the media than Personalis. MarketBeat recorded 6 mentions for Veracyte and 4 mentions for Personalis. Veracyte's average media sentiment score of 0.94 beat Personalis' score of 0.92 indicating that Personalis is being referred to more favorably in the media.
Veracyte has a net margin of -18.16% compared to Veracyte's net margin of -124.89%. Personalis' return on equity of -1.42% beat Veracyte's return on equity.
Veracyte has higher revenue and earnings than Personalis. Veracyte is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.
Veracyte received 320 more outperform votes than Personalis when rated by MarketBeat users. Likewise, 72.93% of users gave Veracyte an outperform vote while only 65.68% of users gave Personalis an outperform vote.
Personalis currently has a consensus price target of $5.00, suggesting a potential upside of 44.93%. Veracyte has a consensus price target of $27.50, suggesting a potential upside of 15.94%. Given Veracyte's stronger consensus rating and higher possible upside, equities research analysts clearly believe Personalis is more favorable than Veracyte.
Summary
Veracyte beats Personalis on 11 of the 18 factors compared between the two stocks.
Get Veracyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Veracyte Competitors List
Related Companies and Tools
